IR@PKUHSC  > 基础医学院  > 细胞生物学系
学科主题基础医学
LAPTM4B-35 Is a Novel Prognostic Factor of Hepatocellular Carcinoma
Yang, Hua1; Xiong, Fuxia1; Qi, Ruizhao2; Liu, Zhenwen2; Lin, Ming1; Rui, Jingan2; Su, Jing3; Zhou, Rouli1
关键词lysosomal protein transmembrane 4 beta (LAPTM4B) Western blot immunohistochemistry (IHC) hepatocellular carcinoma (HCC) prognosis
刊名JOURNAL OF SURGICAL ONCOLOGY
2010-04-01
DOI10.1002/jso.21489
101期:5页:363-369
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Surgery
资助者special fund for promotion of education, Ministry of Education ; 248 major R&amp ; D program of Beijing ; Natural Science Foundation of Beijing ; special fund for promotion of education, Ministry of Education ; 248 major R&amp ; D program of Beijing ; Natural Science Foundation of Beijing
研究领域[WOS]Oncology ; Surgery
关键词[WOS]LIVER-DISEASE ; PHASE-II ; CANCER ; EXPRESSION ; SORAFENIB ; ERLOTINIB ; RESECTION ; THERAPY ; PROTEIN ; MARKER
英文摘要

Background: LAPTM4B-35 is a 35-kDa tetra-transmembrane protein overexpressed in hepatocellular carcinoma (HCC) and promotes cell survival, proliferation, and tumorigenesis. However, the potential clinical implications of LAPTM4B-35 in HCC are still unclear. This study is aimed to investigate the correlations between LAPTM4B-35 expression and prognosis in patients with HCC.

Methods: Western blot and immunohistochemistry assays were used to determine the expression of LAPTM4B-35 in HCCs and their paired noncancerous liver tissues from 65 patients. The correlations of LAPTM4B-35 expression with clinicopathological parameters were assessed by Chi-square test. Patient survival was determined by Kaplan-Meier method and log-rank test. Cox regression was adopted for multivariate analysis of prognostic factors.

Results: LAPTM4B-35 overexpression occurred in 76.9% of HCC tissues, while only in 4.6% of noncancerous liver tissues. Overexpression of LAPTM4B-35 was significantly associated with TNM staging and invasive tumors. Patients with higher LAPTM4B-35 expression had significantly poorer overall survival (OS) and disease-free survival (DFS) (both P < 0.001). On multivariate analysis, elevated expression of LAPTM4B-35 was found to be an independent prognostic factor for OS and DFS (P = 0.009, 0.043, respectively).

Conclusions: LAPTM4B-35 overexpression is an independent prognostic factor for OS and DFS of HCC. J. Surg. Oncol. 2010;101:363-369. (C) 2010 Wiley-Liss, Inc.

语种英语
所属项目编号H020220020310 ; 7041003
资助者special fund for promotion of education, Ministry of Education ; 248 major R&amp ; D program of Beijing ; Natural Science Foundation of Beijing ; special fund for promotion of education, Ministry of Education ; 248 major R&amp ; D program of Beijing ; Natural Science Foundation of Beijing
WOS记录号WOS:000276858500004
引用统计
被引频次:34[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60419
专题基础医学院_细胞生物学系
作者单位1.Peking Univ, Dept Cell Biol, Sch Basic Med Sci, Beijing 100191, Peoples R China
2.302 Hosp Peoples Liberat Army, Dept Liver & Gallbladder Surg, Beijing, Peoples R China
3.Peking Univ, Dept Pathol, Sch Basic Med Sci, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Yang, Hua,Xiong, Fuxia,Qi, Ruizhao,et al. LAPTM4B-35 Is a Novel Prognostic Factor of Hepatocellular Carcinoma[J]. JOURNAL OF SURGICAL ONCOLOGY,2010,101(5):363-369.
APA Yang, Hua.,Xiong, Fuxia.,Qi, Ruizhao.,Liu, Zhenwen.,Lin, Ming.,...&Zhou, Rouli.(2010).LAPTM4B-35 Is a Novel Prognostic Factor of Hepatocellular Carcinoma.JOURNAL OF SURGICAL ONCOLOGY,101(5),363-369.
MLA Yang, Hua,et al."LAPTM4B-35 Is a Novel Prognostic Factor of Hepatocellular Carcinoma".JOURNAL OF SURGICAL ONCOLOGY 101.5(2010):363-369.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fuxia]的文章
[Qi, Ruizhao]的文章
百度学术
百度学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fuxia]的文章
[Qi, Ruizhao]的文章
必应学术
必应学术中相似的文章
[Yang, Hua]的文章
[Xiong, Fuxia]的文章
[Qi, Ruizhao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。